HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis.

AbstractBACKGROUND AND PURPOSE:
Aleglitazar is a dual PPARα/γ agonist but little is known about its effects on vascular function and atherogenesis. Hence, we characterized its effects on circulating angiogenic cells (CAC), neoangiogenesis, endothelial function, arteriogenesis and atherosclerosis in mice.
EXPERIMENTAL APPROACH:
C57Bl/6 wild-type (WT, normal chow), endothelial NOS (eNOS)(-/-) (normal chow) and ApoE(-/-) (Western-type diet) mice were treated with aleglitazar (10 mg·kg(-1) ·day(-1) , i.p.) or vehicle.
KEY RESULTS:
Aleglitazar enhanced expression of PPARα and PPARγ target genes, normalized glucose tolerance and potently reduced hepatic fat in ApoE(-/-) mice. In WT mice, but not in eNOS(-/-) , aleglitazar up-regulated Sca-1/VEGFR2-positive CAC in the blood and bone marrow and up-regulated diLDL/lectin-positive CAC. Aleglitazar augmented CAC migration and enhanced neoangiogenesis. In ApoE(-/-) mice, aleglitazar up-regulated CAC number and function, reduced markers of vascular inflammation and potently improved perfusion restoration after hindlimb ischaemia and aortic endothelium-dependent vasodilatation. This was associated with markedly reduced formation of atherosclerotic plaques. In human cultured CAC from healthy donors and patients with coronary artery disease with or without diabetes mellitus, aleglitazar increased migration and colony-forming units in a concentration-dependent manner. Furthermore, oxidative stress-induced CAC apoptosis and expression of p53 were reduced, while telomerase activity and expression of phospho-eNOS and phospho-Akt were elevated. Comparative agonist and inhibitor experiments revealed that aleglitazar's effects on CAC migration and colony-forming units were mediated by both PPARα and PPARγ signalling and required Akt.
CONCLUSIONS AND IMPLICATIONS:
Aleglitazar augments the number, function and survival of CAC, which correlates with improved vascular function, enhanced arteriogenesis and prevention of atherosclerosis in mice.
AuthorsC M Werner, S H Schirmer, C Gensch, V Pavlickova, J Pöss, M B Wright, M Böhm, U Laufs
JournalBritish journal of pharmacology (Br J Pharmacol) Vol. 171 Issue 10 Pg. 2685-703 (May 2014) ISSN: 1476-5381 [Electronic] England
PMID24467636 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2014 The British Pharmacological Society.
Chemical References
  • Apolipoproteins E
  • Oxazoles
  • PPAR alpha
  • PPAR gamma
  • Thiophenes
  • aleglitazar
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse
Topics
  • Animals
  • Apolipoproteins E (deficiency, genetics)
  • Atherosclerosis (blood, genetics, pathology, physiopathology, prevention & control)
  • Case-Control Studies
  • Cell Movement (drug effects)
  • Cell Proliferation (drug effects)
  • Cells, Cultured
  • Coronary Artery Disease (metabolism, pathology)
  • Disease Models, Animal
  • Endothelial Cells (drug effects, metabolism, pathology)
  • Hindlimb
  • Humans
  • Ischemia (blood, drug therapy, genetics, pathology, physiopathology)
  • Liver (drug effects, metabolism)
  • Male
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Muscle, Skeletal (blood supply)
  • Neovascularization, Physiologic (drug effects)
  • Nitric Oxide Synthase Type III (deficiency, genetics)
  • Oxazoles (pharmacology)
  • PPAR alpha (agonists, metabolism)
  • PPAR gamma (agonists, metabolism)
  • Signal Transduction (drug effects)
  • Stem Cells (drug effects, metabolism, pathology)
  • Thiophenes (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: